NCT01135316View on ClinicalTrials.gov

Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR

CompletedOBSERVATIONAL
Enrollment

2

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Nephrogenic Systemic Fibrosis
Interventions
DRUG

Ablavar

One dose of Ablavar will be administered for use during a contrast MRI examination

Trial Locations (2)

10022

Weill Cornell Medical College, New York

27710

Duke University Medical Center, Durham

Sponsors
All Listed Sponsors
lead

Lantheus Medical Imaging

INDUSTRY